Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis

2024-9-13

Clinical experience of using biosimilars in Crohn’s disease and their effectiveness

2024-9-13

Mosunetuzumab for the treatment of follicular lymphoma

2024-9-11

Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian Countries: a survey study

2024-9-5

The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target

2024-9-4

An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia

2024-9-2

The future of aptamers in cancer diagnosis, prognosis and treatment

2024-8-30

Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors

2024-8-30

T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement

2024-8-26

Perispinal etanercept stroke trial design: PESTO and beyond

2024-8-23

The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma

2024-8-22

Current status and new avenues of stem cell-based preclinical and therapeutic approaches in amyotrophic lateral sclerosis

2024-8-20

The FDA approval of delandistrogene moxeparvovec-rokl for duchenne muscular dystrophy: a critical examination of the evidence and regulatory process

2024-8-17

IL-17 inhibitors in axial spondyloarthritis. An overview

2024-8-17

How comparative studies can inform treatment decisions for Crohn’s disease

2024-8-12

Clinical management and innovation in fracture non-union

2024-8-10

Correction

2024-8-8

The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations

2024-8-7

Correction

2024-8-2

Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19

2024-8-2

Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center

2024-8-2

The chimera of reaching a universal consensus on platelet-rich plasma treatment for knee osteoarthritis: a review of recent consensus statements and expert opinion

2024-7-29

Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies

2024-7-29

Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases

2024-7-27

Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis

2024-7-25

The nail in psoriatic arthritis: new insights into prognosis and treatment

2024-7-24

The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review

2024-7-24

The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis

2024-7-22

Long acting delivery and therapies for neovascular age-related macular degeneration

2024-7-22

Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease

2024-7-18

Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience

2024-7-8

Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan

2024-7-6

Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis

2024-7-4

Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer

2024-6-25

Targeting gut and intratumoral microbiota: a novel strategy to improve therapy resistance in cancer with a focus on urologic tumors

2024-6-24

Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents.

2024-6-24

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study

2024-6-21

Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market

2024-6-6

Management of proctitis in ulcerative colitis and the place of biological therapies

2024-6-2

Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma

2024-6-2

How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?

2024-6-2

Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond

2024-6-2

Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?

2024-6-2

Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps

2024-6-2

Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures

2024-6-2

Checkpoint inhibition for early-stage hormone receptor-positive breast cancer

2024-6-2

Gene therapy for Leber hereditary optic neuropathy

2024-6-2

Treatment options for advanced hepatocellular carcinoma: the potential of biologics

2024-6-2

Small molecule-regulated switches to provide functional control of CAR T cells within the patient

2024-6-2

An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer

2024-6-2